Zacks Investment Research
30 Jul 2026, 23:06 UTC · 3d ago
Veracyte (VCYT) Q2 Earnings and Revenues Surpass Estimates
NewsImpactScreener rates every claim in this story for market impact and maps it to the tickers most exposed.
Zacks Investment Research
30 Jul 2026, 23:06 UTC · 3d ago
NewsImpactScreener rates every claim in this story for market impact and maps it to the tickers most exposed.
What the story claims
3 claims · each scored for market impact
Veracyte reported quarterly earnings of $0.54 per share, exceeding the Zacks Consensus Estimate of $0.43 per share. — An earnings beat of 25.58% typically triggers a positive immediate price reaction for the specific security.
+0.40Veracyte's quarterly revenue reached $150.32 million, surpassing the consensus estimate by 4.13%. — Top-line growth and a revenue beat support the company's fundamental strength and growth trajectory.
+0.30Veracyte currently holds a Zacks Rank #4 (Sell) due to an unfavorable trend in earnings estimate revisions prior to the report. — A 'Sell' rating from a major research tool suggests bearish sentiment or poor future outlook that could cap upside gains.
-0.30Which stocks this story touches
Continue reading
6 related stories
Top 1 mover · tap to explore
The company beat both earnings and revenue estimates for the quarter and has a strong history of beating consensus.
Free · No account
Get a free daily PDF briefing — the last 24 hours of news, with summaries and the market-impact score for each story, delivered an hour before the open.
We’ll watch
Pre-filled from this story — remove any you don’t want. Add more tickers & tags or fine-tune your watchlist anytime — every email has an edit link, no account needed.
Free forever · one email a day, max · unsubscribe in one click.How it works
How the impact breaks down
Where the story's weight lands
Stocks most exposed
Modeled from each name's sensitivity to this story
Benzinga
52m ago
Seeking Alpha
7h ago
